Optimizing In-Situ Forming Implants for Controlled Drug Release in Parkinson’s Disease Treatment

Introduction: Parkinson’s disease is a debilitating neurodegenerative disorder. Conventional therapies are available for Parkinson’s disease are associated with limitations such as the wearing-off effect, on-off period, and episodes of motor freezing (1). Reports suggest that such side effects are mainly due to the fluctuation in the plasma concentration of the drugs, which necessitates multiple doses for attending the therapeutic level. Our current hypothesis is to develop a long-acting injectable gel that will release the drug slowly for up to 1 week avoiding fluctuations in plasma concentration.

Yunmei Song – Lab manager, Clinical and health Sciences, University of South Australia; Sanjay Garg – Professor, Clinical and health Sciences, University of South Australia